Nadja Jäkel

433 total citations
12 papers, 183 citations indexed

About

Nadja Jäkel is a scholar working on Hematology, Genetics and Oncology. According to data from OpenAlex, Nadja Jäkel has authored 12 papers receiving a total of 183 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Hematology, 5 papers in Genetics and 5 papers in Oncology. Recurrent topics in Nadja Jäkel's work include Acute Myeloid Leukemia Research (3 papers), Multiple Myeloma Research and Treatments (3 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (3 papers). Nadja Jäkel is often cited by papers focused on Acute Myeloid Leukemia Research (3 papers), Multiple Myeloma Research and Treatments (3 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (3 papers). Nadja Jäkel collaborates with scholars based in Germany, United Kingdom and France. Nadja Jäkel's co-authors include Dietger Niederwieser, Haifa Kathrin Al‐Ali, Jacqueline Maier, Rainer Krahl, Claudia Wickenhauser, Michael Cross, Heinz Gisslinger, Viktoriya Stalbovskaya, Mary Frances McMullin and Hilde Demuynck and has published in prestigious journals such as Blood, British Journal of Haematology and Haematologica.

In The Last Decade

Nadja Jäkel

12 papers receiving 180 citations

Peers

Nadja Jäkel

HEMAT

GENET

ONCOL

RHEUM

Emily A. Rosen United States

Farhad Ravandi United States

Simone Claudiani United Kingdom

Erika Morsia Italy

N. Pollicardo Italy

Maria Chiara Abbenante Italy

Eveline S. de Bont Netherlands

Atanas Radinoff Bulgaria

Desiree De Lange Netherlands

Kristina Myhr‐Eriksson Sweden

Emily A. Rosen United States

Nadja Jäkel

199 ×1.6

HEMAT

230 ×2.2

GENET

160 ×1.9

17 ×0.4

ONCOL

63 ×1.4

RHEUM

Citations per year, relative to Nadja Jäkel Nadja Jäkel (= 1×) peers Emily A. Rosen

Countries citing papers authored by Nadja Jäkel

Since Specialization

Citations

This map shows the geographic impact of Nadja Jäkel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nadja Jäkel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nadja Jäkel more than expected).

Fields of papers citing papers by Nadja Jäkel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nadja Jäkel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nadja Jäkel. The network helps show where Nadja Jäkel may publish in the future.

Co-authorship network of co-authors of Nadja Jäkel

This figure shows the co-authorship network connecting the top 25 collaborators of Nadja Jäkel. A scholar is included among the top collaborators of Nadja Jäkel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nadja Jäkel. Nadja Jäkel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

Bauer, Marcus, Nadja Jäkel, Markus Eszlinger, et al.. (2024). Prognostic impact of the bone marrow tumor microenvironment, HLA-I and HLA-Ib expression in MDS and CMML progression to sAML. OncoImmunology. 13(1). 2323212–2323212. 2 indexed citations

Goekbuget, Nicola, Stefan Schwartz, Christoph Faul, et al.. (2023). Dose Reduced Chemotherapy in Sequence with Blinatumomab for Newly Diagnosed Older Patients with Ph/BCR::ABL Negative B-Precursor Adult Lymphoblastic Leukemia (ALL): Preliminary Results of the GMALL Bold Trial. Blood. 142(Supplement 1). 964–964. 20 indexed citations

Grimm, Juliane, Donjetë Simnica, Nadja Jäkel, et al.. (2022). Azacitidine-induced reconstitution of the bone marrow T cell repertoire is associated with superior survival in AML patients. Blood Cancer Journal. 12(1). 19–19. 11 indexed citations

Leblanc, Thierry, Mohamed Touati, Fanny Fouyssac, et al.. (2017). Non syndromic childhood onset congenital sideroblastic anemia: A report of 13 patients identified with an ALAS2 or SLC25A38 mutation. Blood Cells Molecules and Diseases. 66. 11–18. 14 indexed citations

McMullin, Mary Frances, Claire Harrison, Dietger Niederwieser, et al.. (2015). The use of erythropoiesis-stimulating agents with ruxolitinib in patients with myelofibrosis in COMFORT-II: an open-label, phase 3 study assessing efficacy and safety of ruxolitinib versus best available therapy in the treatment of myelofibrosis. Experimental Hematology and Oncology. 4(1). 26–26. 35 indexed citations

Krahl, Rainer, Nadja Jäkel, Michael Cross, et al.. (2013). JAK2 p.V617F allele burden in myeloproliferative neoplasms one month after allogeneic stem cell transplantation significantly predicts outcome and risk of relapse. Haematologica. 98(5). 722–728. 48 indexed citations

Pönisch, Wolfram, Simone Heyn, Ina Wagner, et al.. (2013). Lenalidomide, bendamustine and prednisolone exhibits a favourable safety and efficacy profile in relapsed or refractory multiple myeloma: final results of a phase 1 clinical trial OSHO – #077. British Journal of Haematology. 162(2). 202–209. 22 indexed citations

McMullin, Mary Frances, Claire Harrison, Dietger Niederwieser, et al.. (2012). The Use of Erythropoietic-Stimulating Agents (ESAs) with Ruxolitinib in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), and Post-Essential Thrombocythemia Myelofibrosis (PET-MF).. Blood. 120(21). 2838–2838. 12 indexed citations

Heyn, Simone, Nadja Jäkel, Robert Rohrberg, et al.. (2012). Combined Bendamustine, Prednisone and Bortezomib (BPV) in Patients with Relapsed or Refractory Multiple Myeloma. Blood. 120(21). 1855–1855. 2 indexed citations

10.

Singer, Susanne, Heide Götze, Anna Brown, et al.. (2012). A non-randomised trial of an art therapy intervention for patients with haematological malignancies to support post-traumatic growth. Journal of Health Psychology. 18(7). 939–949. 12 indexed citations

11.

Pönisch, Wolfram, Simone Heyn, Ina Wagner, et al.. (2010). Combined Bendamustine, Prednisolone and Lenalidomide (RBP) In Refractory or Relapsed Multiple Myeloma. First Results of a Phase I Clinical Trial. Blood. 116(21). 1971–1971. 2 indexed citations

12.

Hudecek, Michael, Nadja Jäkel, Simone Heyn, et al.. (2008). Spontaneous Remission of Acute Myeloid Leukemia Relapse after Hematopoietic Cell Transplantation in a High-Risk Patient with 11q23/MLL Abnormality. Acta Haematologica. 119(2). 111–114. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact